Internal sdAb Discovery Program
Undisclosed
DiscoveryActive
Key Facts
About NanoTag Biotechnologies
NanoTag Biotechnologies is a private, revenue-generating platform and services company specializing in the discovery, engineering, and production of single-domain antibodies (nanobodies). Its core business model combines a portfolio of validated research reagents (e.g., FluoTags®, Smart Secondaries®, Selector resins) with custom contract research services for sdAb discovery and protein production. The company has secured a significant strategic partnership with BioNTech to evaluate its proprietary ALFA labeling technology across therapeutic areas, indicating a strategic pivot towards therapeutic and diagnostic applications alongside its strong R&D tools business.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |
| Therapeutic Programs | Agathos Biologics | Pre-clinical |